Edgewise Therapeutics (EWTX) News
NASDAQ: EWTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
39.06-0.17 (-0.43%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
EWTX news summary
We found 2 recent headlines mentioning Edgewise Therapeutics (EWTX): 1 in the past week and 2 in the past 30 days, most often from Nasdaq. For price context, EWTX is down 0.43% at $39.06. The most recent story, "Edgewise Therapeutics Doses First Patient In Phase 2 HFpEF Trial; Stock Down", was published by Nasdaq on Oct 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Edgewise Therapeutics headlines
- Edgewise Therapeutics Doses First Patient In Phase 2 HFpEF Trial; Stock Down(RTTNews) - Edgewise Therapeutics (EWTX) announced that the first patient has been dosed in the Phase 2 EQUINOX-HFpEF trial evaluating EDG-15400 in adults with symptomatic heart failure with…NasdaqEWTX, BRK.B
- Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.NasdaqBMY, CYTK, EWTX